901929-01-9

Usage

General Description

3-(4-(benzyloxy)phenyl)isoxazole-5-carboxylic acid is a chemical compound with the molecular formula C19H15NO4. It is an isoxazole derivative that contains a carboxylic acid functional group. The compound is commonly used in medicinal chemistry and drug development due to its potential biological activity. Its structure includes a phenyl group, a benzyloxy group, and an isoxazole ring, all of which contribute to its pharmacological properties. Additionally, the carboxylic acid group allows for easy modification of the compound to optimize its activity. Overall, 3-(4-(benzyloxy)phenyl)isoxazole-5-carboxylic acid has potential applications in the pharmaceutical industry for the development of new drugs with improved biological activity.

Upstream product

• 188038-42-8 4-benzyloxy-N-hydroxy-benzenecarboximidoyl chloride 
• 123-08-0 4-hydroxy-benzaldehyde 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 1210761-18-4 ethyl 3-(4-(benzyloxy)phenyl)isoxazole-5-carboxylate 

Downstream Products

• 1210761-12-8 methyl 2-(3-(4-(benzyloxy)phenyl)isoxazole-5-carboxamido)-3-methylbutanoate 
• 1394039-30-5 2-(3-(4-(4-fluorobenzyloxy)phenyl)isoxazole-5-carboxamido)-3-methylbutanoic acid 

Relevant academic research and scientific papers

Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors

Diacylglycerol acyltransferase, DGAT1, is a promising target enzyme for obesity due to its involvement in the committed step of triglyceride biosynthesis. Amino biphenyl carboxylic acids, exemplified by compound 4, are known potent inhibitors of hDGAT1. However the high cLogP and poor solubility of these biphenyl analogs might tend to limit their development. We have synthesized and evaluated compounds containing 3-phenylisoxazole, 5-phenyloxazole, and 3-phenyl-1,2,4-oxadiazole biaryl units for their hDGAT1 inhibition. Our aim in synthesizing such heterocyclic analogs was to improve the cLogP and solubility of these molecules while retaining hDGAT1 potency. Several compounds within the 3-phenylisoxazole series exhibited potent hDGAT1 inhibition when evaluated using an in vitro enzymatic assay. Certain promising compounds were studied for their potential to reduce triglyceride levels using an in vivo fat tolerance test in mice and were also evaluated for any possible improvement to their solubility. Compound 40a (IC50 = 64 nM) with an in vivo plasma triglyceride reduction of 90 percent, and a solubility of 0.43 mg/ml at pH 7.4 may serve as a new lead for developing newer anti-obesity agents.

OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS

The present invention relates to isoxazole, thiazole and oxidiazole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular to the use of these compounds in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1.